A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Vaccine
- Publicado em
- 12 fev 2025
- Citações
- 8
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older
Brandon J Essink, Wim Vermeulen, Coralie Andrade, Richard de Rooij, Leah Isakov, Daniela Casula, Frank R Albano
Descritores MeSH
- Adjuvants, Vaccine
- Influenza, Human
- Polysorbates
- Squalene
- Influenza Vaccines
- Immunogenicity, Vaccine
- Hemagglutination Inhibition Tests
- Humans
- Male
- Middle Aged
Veja também
Estudos relacionados
- Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59®
- A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults
- Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults
- Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial